Newron Pharmaceuticals First Half 2024 Earnings: €0.52 loss per share (vs €0.39 loss in 1H 2023)

Newron Pharmaceuticals (VTX:NWRN) First Half 2024 Results

Key Financial Results

• Revenue: €3.41m (down 38% from 1H 2023).
• Net loss: €9.56m (loss widened by 38% from 1H 2023).
• €0.52 loss per share (further deteriorated from €0.39 loss in 1H 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Newron Pharmaceuticals Earnings Insights

Looking ahead, revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in Switzerland.

Performance of the Swiss Pharmaceuticals industry.

The company's shares are down 10% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 4 warning signs for Newron Pharmaceuticals (2 are potentially serious!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.